Please ensure Javascript is enabled for purposes of website accessibility

COVID-19 Pushes Cancer Conference Into a Virtual Format

By Cory Renauer - Mar 25, 2020 at 9:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The American Society of Clinical Oncology's annual meeting -- one of the most important healthcare industry gatherings of the year -- will happen without face-to-face contact.

A string of scientific breakthroughs in recent years has made oncology the most-watched corner of the biopharmaceutical industry, and many of those breakthroughs were first presented at the American Society of Clinical Oncology's (ASCO) annual meeting.

However, gathering scientists from all over the world and squeezing them into conference rooms isn't going to happen during the COVID-19 pandemic. Instead of canceling the whole show, ASCO recently announced that the 2020 meeting, scheduled for May 29 through June 2, will occur on schedule in a virtual format that doesn't require attendees to travel to Chicago. 

Working from home with a facemask.

Image source: Getty Images.

In the weeks ahead, ASCO will post more details regarding formats, dates, and many other aspects of the annual conference. What we do know is that ASCO plans to publish abstracts online ahead of the conference as is usually the case. Researchers will probably get a chance to deliver some form of an online presentation, but we'll just have to wait to find out how. 

Investment bank analysts permeate scientific conferences like ASCO, which makes them crucial venues for smaller biotechnology companies like Trillium Therapeutics (TRIL), and Harpoon Therapeutics (HARP -0.96%) that need fresh influxes of capital to keep their research moving forward.

At ASCO this year, Trillium expects to present details from an early-stage clinical trial of its experimental treatment TTI-622 in relapsed lymphoma patients. Harpoon is expected to share interim data from a study of HPN424, a potential new treatment for advanced-stage prostate cancer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Harpoon Therapeutics, Inc. Stock Quote
Harpoon Therapeutics, Inc.
$2.06 (-0.96%) $0.02
Trillium Therapeutics Inc. Stock Quote
Trillium Therapeutics Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.